182 related articles for article (PubMed ID: 29578036)
1. mGlu
Charvin D
Neuropharmacology; 2018 Jun; 135():308-315. PubMed ID: 29578036
[TBL] [Abstract][Full Text] [Related]
2. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
[TBL] [Abstract][Full Text] [Related]
3. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease.
Lindsley CW; Niswender CM; Engers DW; Hopkins CR
Curr Top Med Chem; 2009; 9(10):949-63. PubMed ID: 19754407
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
7. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Amalric M
Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
9. mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
East SP; Gerlach K
Expert Opin Ther Pat; 2010 Mar; 20(3):441-5. PubMed ID: 20180624
[TBL] [Abstract][Full Text] [Related]
10. Mavoglurant as a treatment for Parkinson's disease.
Petrov D; Pedros I; de Lemos ML; Pallàs M; Canudas AM; Lazarowski A; Beas-Zarate C; Auladell C; Folch J; Camins A
Expert Opin Investig Drugs; 2014 Aug; 23(8):1165-79. PubMed ID: 24960254
[TBL] [Abstract][Full Text] [Related]
11. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
[TBL] [Abstract][Full Text] [Related]
12. A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model?
Doller D; Bespalov A; Miller R; Pietraszek M; Kalinichev M
Expert Opin Investig Drugs; 2020 Dec; 29(12):1323-1338. PubMed ID: 33074728
[TBL] [Abstract][Full Text] [Related]
13. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.
Niswender CM; Johnson KA; Weaver CD; Jones CK; Xiang Z; Luo Q; Rodriguez AL; Marlo JE; de Paulis T; Thompson AD; Days EL; Nalywajko T; Austin CA; Williams MB; Ayala JE; Williams R; Lindsley CW; Conn PJ
Mol Pharmacol; 2008 Nov; 74(5):1345-58. PubMed ID: 18664603
[TBL] [Abstract][Full Text] [Related]
14. Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Gubellini P; Melon C; Dale E; Doller D; Kerkerian-Le Goff L
Neuropharmacology; 2014 Oct; 85():166-77. PubMed ID: 24866785
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Picconi B; Calabresi P
Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu
Engers DW; Bollinger SR; Engers JL; Panarese JD; Breiner MM; Gregro A; Blobaum AL; Bronson JJ; Wu YJ; Macor JE; Rodriguez AL; Zamorano R; Conn PJ; Lindsley CW; Niswender CM; Hopkins CR
Bioorg Med Chem Lett; 2018 Aug; 28(15):2641-2646. PubMed ID: 29958762
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of a novel CNS penetrant series of mGlu
Kent CN; Fulton MG; Stillwell KJ; Dickerson JW; Loch MT; Rodriguez AL; Blobaum AL; Boutaud O; Rook JL; Niswender CM; Conn PJ; Lindsley CW
Bioorg Med Chem Lett; 2021 Apr; 37():127838. PubMed ID: 33556572
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of targeting glutamate receptors in Parkinson's disease.
Finlay C; Duty S
J Neural Transm (Vienna); 2014 Aug; 121(8):861-80. PubMed ID: 24557498
[TBL] [Abstract][Full Text] [Related]
19. The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu
Panarese JD; Engers DW; Wu YJ; Guernon JM; Chun A; Gregro AR; Bender AM; Capstick RA; Wieting JM; Bronson JJ; Macor JE; Westphal R; Soars M; Engers JE; Felts AS; Rodriguez AL; Emmitte KA; Jones CK; Blobaum AL; Conn PJ; Niswender CM; Hopkins CR; Lindsley CW
Bioorg Med Chem Lett; 2019 Jan; 29(2):342-346. PubMed ID: 30503632
[TBL] [Abstract][Full Text] [Related]
20. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.
Ellaithy A; Younkin J; González-Maeso J; Logothetis DE
Trends Neurosci; 2015 Aug; 38(8):506-16. PubMed ID: 26148747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
